Literature DB >> 10331700

Correlation between rates of brain atrophy and cognitive decline in AD.

N C Fox1, R I Scahill, W R Crum, M N Rossor.   

Abstract

Twenty-nine untreated patients diagnosed with probable AD and 15 control patients underwent two or more clinical and volumetric MRI assessments with intervals ranging from 5 months to 6 years. The change in global cerebral volume for an individual was calculated by a novel method of registration and subtraction of serial scans. Rate of global cerebral volume loss correlated strongly with rate of change in Mini-Mental State Examination scores (r = 0.80, p < 0.001), implying clinical relevance to this marker of progression.

Entities:  

Mesh:

Year:  1999        PMID: 10331700     DOI: 10.1212/wnl.52.8.1687

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  123 in total

1.  The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.

Authors:  Mert R Sabuncu; Randy L Buckner; Jordan W Smoller; Phil Hyoun Lee; Bruce Fischl; Reisa A Sperling
Journal:  Cereb Cortex       Date:  2011-12-13       Impact factor: 5.357

2.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

Authors:  C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

Review 3.  Imaging Alzheimer's disease.

Authors:  Scott A Small
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

Review 4.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

5.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 6.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

7.  Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort.

Authors:  Charles H Brown; A Richey Sharrett; Josef Coresh; Andrea L C Schneider; Alvaro Alonso; David S Knopman; Thomas H Mosley; Rebecca F Gottesman
Journal:  Neurology       Date:  2015-03-11       Impact factor: 9.910

Review 8.  Atrial fibrillation, cognition and dementia: A review.

Authors:  Summer Aldrugh; Mayank Sardana; Nils Henninger; Jane S Saczynski; David D McManus
Journal:  J Cardiovasc Electrophysiol       Date:  2017-06-21

Review 9.  Mild cognitive impairment: ten years later.

Authors:  Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2009-12

10.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.